Standout Papers

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival res... 2015 2026 2018 2022 878
  1. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) (2017)
    Jacob Schachter, Antoni Ribas et al. The Lancet
  2. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study (2019)
    Caroline Robert, Antoni Ribas et al. The Lancet Oncology
  3. Clinical implications of the intrinsic molecular subtypes of breast cancer (2015)
    Aleix Prat, Estela Pineda et al. The Breast
  4. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study (2019)
    Georgina V. Long, Reinhard Dummer et al. The Lancet Oncology
  5. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial (2018)
    Reinhard Dummer, Paolo A. Ascierto et al. The Lancet Oncology
  6. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial (2017)
    Michael A. Davies, Philippe Saïag et al. The Lancet Oncology
  7. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial (2018)
    Reinhard Dummer, Paolo A. Ascierto et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 11 from Science/Nature 67 standout
Sub-graph 1 of 21

Citing Papers

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
2025 Standout
Dendritic cell maturation in cancer
2025 Standout

Works of Ana Arance being referenced

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
2019 Standout
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
2018 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Ana Arance 6070 3995 2032 176 8.2k
Anna C. Pavlick 5666 4641 2166 216 8.7k
René González 6499 4272 2587 188 9.0k
Helen Gogas 6319 3737 2158 326 8.9k
Paola Queirolo 5242 2947 2450 229 7.1k
James S. Wilmott 4333 2770 2348 137 6.2k
Bartosz Chmielowski 4349 2542 1769 179 6.8k
Kevin B. Kim 5059 5324 1003 114 8.1k
David Hogg 3865 3206 1137 121 6.2k
Jacob Schachter 6291 2924 2908 184 8.2k
Shanu Modi 5555 2611 789 227 8.3k

All Works

Loading papers...

Rankless by CCL
2026